Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual effects.
Jacque Duncan, MD
Advertisement
Articles by Jacque Duncan, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
AAO 2026: Optogenetic gene therapy heads to phase 2 trial in geographic atrophy
2
AAO 2026: BRUNELLO 1-year results for remigromig in DME
3
AAO 2026: MCO-010 sustains vision gains in RP through 4 years
4
AAO 2026: DAYBREAK shows tarcocimab and tabirafusp-ted noninferior to aflibercept in wet AMD
5